Abstract
Compliance with antihypertensive therapy decreases over time and as the number of pills increases. This case describes a 64-year-old male with hypertension who was initially prescribed antihypertensive therapy with olmesartan (OLM) once daily in the morning and amlodipine (AML) once daily in the evening. Reductions in blood pressure (BP) were observed, but BP control was not achieved. Therefore, an evening dose of hydrochlorothiazide (HCTZ) was added to the treatment regimen. Despite stating that he was adhering to therapy, the patient’s prescription records indicated otherwise. The patient was switched to an OLM/AML/HCTZ single-pill fixed-dose combination and BP had decreased to the normal range at a follow-up visit 3 months later.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16:S24–8.
Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283–91.
Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23:419–30.
Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens. 2007;9:187–95.
Materson BJ, Reda DJ, Cushman WC. Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189–92.
Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7.
Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.
Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52.
Acknowledgments
The authors wish to thank Renata Perego, Nicola Ryan and Raelene Simpson, independent medical writers, who provided editorial assistance on behalf of Springer Healthcare Communications. This assistance was supported by the Menarini group.
Conflict of interest
Dr. Sarafidis has served as a speaker/advisor for AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, the Menarini group and Daiichi Sankyo. The activities conducted with the support of the Menarini group do not constitute a conflict of interest in relation to the contents of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Please refer to the approved SmPC for the correct use of the drugs mentioned in this article.
Rights and permissions
About this article
Cite this article
Sarafidis, P.A. Patient Cases: 1. A Patient with Apparent Compliance. High Blood Press Cardiovasc Prev 22 (Suppl 1), 15–18 (2015). https://doi.org/10.1007/s40292-015-0109-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40292-015-0109-0